Anupam Rasayan India Ltd. (ARIL), one of India’s leading custom synthesis and specialty chemical players, has announced Q2 FY23 operating  revenues at Rs. 308.7 crore as compared to Rs. 255.2 crore in Q2FY22, a growth of 21% Y-o-Y.

EBITDA (incl. other revenue) at Rs. 89.8 crore in Q2 FY23 as compared to Rs. 69.7 crore in Q2 FY22, a growth of 29% Y-o-Y.

Profit After Tax at Rs. 41.2 crore in Q2 FY23 as compared to Rs. 35.8 crore in Q2FY22, a growth of 15% Y-o-Y.

Anand Desai, Managing Director, Anupam Rasayan said, “I am delighted to inform you that our standalone business grew by 25% year on year to Rs. 310 crore with  the consistent EBITDA margins. Our philosophy of carrying a long-term vision in our business conduct is bearing its fruits as Anupam has started seeing the benefits of this Europe+1 trend with our latest announcement of signing two contracts with one of the European Crop Protection companies for supplying two new life science related specialty chemicals."

"Overall, we continue to see upward bias in all the contracted volumes with major customers. This makes us confident of delivering a strong performance in the coming quarters and for the year,” added Desai.

ARIL is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India and has two verticals: Life science related Specialty Chemicals comprising products related to agrochemicals, personal care, and pharmaceuticals; and Other Specialty Chemicals comprising specialty pigment and dyes, and polymer additives.

The company operates via its six manufacturing facilities in Gujarat, India, with four facilities located at Sachin, Surat and two located at Jhagadia, Bharuch with an aggregate installed capacity of about 27,000 MT, as of March 31, 2022.